Elanco Animal Health Inc 2Q 2026: Revenue $1.37B, EPS $0.11— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Elanco Animal Health Inc reported Q2 2026 revenue of $1.37B, up 10% year-over-year, and returned to profitability with diluted EPS of $0.11. Growth was driven by pet health and farm animal volume gains, pricing, and new product launches like Zenrelia. The company completed the AHV acquisition in April 2026 and continues its 2025 restructuring plan to drive future savings.
Elanco Animal Health Inc reported second-quarter 2026 results with revenue up 10% year over year and a return to profitability, driven by pet health and farm animal volume gains, pricing, and recent product launches.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $1.37B | $1.24B | 10.2% |
| Net income² | $54M | $11M | 390.9% |
| Diluted EPS³ | $0.11 | $0.02 | 450% |
¹ Reported as “Revenue”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by pet health and farm animal volume gains and pricing, with omnichannel distribution across veterinary clinics, retail and e-commerce.
- New product launches including Zenrelia, Credelio Quattro and Befrena are gaining adoption and contributing incremental sales.
- Completed the AHV acquisition on April 30, 2026, to expand the farm animal portfolio; the acquisition contributed modest revenue in 2026.
- Ongoing 2025 Restructuring Plan includes R&D consolidation (Monheim exit, Indy expansion) and exit of the Kansas City plant to drive future savings.
- Approximately 52% of revenue is generated in non‑USD markets, affecting geographic mix and results.
Original SEC Filing: Elanco Animal Health Inc [ ELAN ] - 10-Q - Aug. 05, 2026